Radius Health (Nasdaq: RDUS) is moving to session lows Monday after the company announced the presentation of positive top-line data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Trader Talk

Radius Health (RDUS) Presents Positive Top-Line Data from ACTIVExtend Phase 3 in Postmenopausal OsteoporosisOctober 12, 2015 2:32 PM Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With OsteoporosisOctober 12, 2015 2:30 PM Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation October 12, 2015 9:10 AM Radius Health (RDUS) Presents Positive Phase 3 Data from ACTIVE Trial at ASBMR MeetingOctober 12, 2015 6:51 AM Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual MeetingOctober 10, 2015 7:15 PM